Eagle Falls After CRL For Ready-To-Use Angiomax Product Kangio
This article was originally published in Scrip
Executive Summary
Eagle Pharmaceuticals Inc. fell 19% to close at $43.50 per share on March 18 after the company said it received a complete response letter (CRL) rejecting an application for US FDA approval of Eagle's ready-to-use (RTU) version of Angiomax (bivalirudin) known as Kangio (bivalirudin RTU).